Search 

Alliance Pharma is an internation specialty pharma busienss with a buy and build business model and asset light operations. We have a balanced portoflio of growth focussed international star brands and a cash-generative Bedrock requiring minimal promotional support. We have 20 years of operation, 35 deals experience and have been on the London stock exchange junior market (AIM) since 2003 (LSE: APH). 2017 results: £100m+ sales, 27% EBITDA, £20m+ FCF, dividend paying Our star brands are: Kelo-cote – fastest drying, silicone gel anti-scar treatment  MacuShield – exact match to the protective pigments found on the macula Vamousse – most technologically advanced treatment for head lice Nizoral – medicated anti-dandruff shampoo acquired from J&J in June 2018      

Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, OTC and biosimilar products around the world.

A unique portfolio of high-quality and difficult-to-make products fuels our targeted growth strategy.

The company has commercial operations in 35 countries with 2,800 employees and operates five manufacturing and development hubs in the U.S., Romania, Korea and Taiwan.

Alvogen's product portfolio consists of a broad range of leading molecules for the treatment of conditions in the areas of oncology, cardiology, respiratory, Women Health, neurology and gastroenterology, in addition to a fast-growing portfolio of biosimilars and OTC products.  

Angelini, established in 1919, is a privately-held, family owned international Group with a consolidated revenue for 2017 of € 1,7 billion. Pharma represents the core business of Angelini family, with a revenue of € 851 million.

Headquartered in Rome, Italy, Angelini Pharma is a fully integrated company from R&D to Commercial and operates directly in more than twenty countries, including Italy, Spain, Central Eastern European countries, Russia and Turkey.

Angelini focuses his research and commercial activities mainly on Pain, Infectious Diseases and Central Nervous System.

R&D Department has full development capabilities from discovery to clinical and it has currently development programs ongoing in all the core therapeutic areas. Amongst others, R&D synthetized and developed both Benzydamine- for treatment of Sore throat- and Trazodone- for treatment of Major Depression- two molecules worldwide present either through Angelini direct operations or licensing-out deals.

Angelini field force- that counts more than 1.100 professionals - promotes a wide range of products coming both from internal development and licensing agreements, targeting and detailing a number of Healthcare professionals ranging from Pharmacist and General Practitioner to specialty care physicians of Psychiatry, Neurology, Infectious Disease, Pain, Oncology, Paediatric and Gynaecology.

Angelini represents a partner of choice for new product licenses for its territories with ready-to-use capabilities in terms of Regulatory, Market Access, Medical and Commercial. A list of partners of Angelini includes amongst others Helsinn, Incyte, Allergan, Dainippon Sunovion, Gilead, Zambon, Fidia, Almirall and Expanscience. Business Development is looking for innovative products in late stage development in Pain, Infectious Disease and CNS with companies interested in long-term partnership. M&A and Divestment opportunities are also in the scope when there’s a fitting to Angelini focus and Geography.